Dupilumab reduces need for systemic corticosteroid use, sinonasal surgery in patients with severe chronic rhinosinusitis with nasal polyps: Pooled results from the SINUS-24, SINUS-52 phase 3 studies

被引：0

作者：

Desrosiers, M. ^{[1
]}

Bachert, C. ^{[2
,3
]}

Hellings, P. W. ^{[4
]}

Hopkins, C. ^{[5
]}

Olze, H. ^{[6
]}

Han, J. K. ^{[7
]}

Lee, S. E. ^{[8
]}

Zhang, M. ^{[9
]}

Lu, X. ^{[9
]}

Amin, N. ^{[10
]}

Patel, N. ^{[9
]}

Graham, N. M. H. ^{[10
]}

Ruddy, M. ^{[10
]}

Staudinger, H. ^{[9
]}

Mannent, L. P. ^{[11
]}

机构：

[1] CRCHUM, Montreal, PQ, Canada

[2] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium

[3] Karolinska Inst, Stockholm, Sweden

[4] Univ Hosp Leuven, Leuven, Belgium

[5] Guys & St Thomas Hosp, London, England

[6] Charite Univ Med Berlin, Dept Otorhinolaryngol Head & Neck Surg, Berlin, Germany

[7] Eastern Virginia Med Sch, Norfolk, VA 23501 USA

[8] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[9] Sanofi, Bridgewater, MA USA

[10] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[11] Sanofi, Chilly Mazarin, France

来源：

ALLERGY | 2019年 / 74卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

PD0613

引用

页码：330 / 331

页数：2

共 42 条

[31] Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Bachert, Claus
Han, Joseph K.
Desrosiers, Martin
Hellings, Peter W.
Amin, Nikhil
Lee, Stella E.
Mullol, Joaquim
Greos, Leon S.
Bosso, John V.
Laidlaw, Tanya M.
Cervin, Anders U.
Maspero, Jorge F.
Hopkins, Claire
Olze, Heidi
Canonica, G. Walter
Paggiaro, Pierluigi
Cho, Seong H.
Fokkens, Wytske J.
Fujieda, Shigeharu
Zhang, Mei
Lu, Xin
Fan, Chunpeng
Draikiwicz, Steven
Kamat, Siddhesh A.
Khan, Asif
Pirozzi, Gianluca
Patel, Naimish
Graham, Neil M. H.
Ruddy, Marcella
Staudinger, Heribert
Weinreich, David
Stahl, Neil
Yancopoulos, George D.
Mannent, Leda P.
LANCET, 2019, 394 (10209) : 1638 - 1650
[32] Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial
Bachert, Claus
Mullol, Joaquim
Daizadeh, Nadia
Wolfe, Kelley
Ortiz, Benjamin
Johnson, Robert
Deniz, Yamo
Rowe, Paul
Mannent, Leda
Amin, Nikhil
Harel, Sivan
Jagerschmidt, Alexandre
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[33] Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials
Mullol, Joaquim
Laidlaw, Tanya M.
Amin, Nikhil
Bachert, Claus
Han, Joseph K.
Hellings, Peter W.
Canonica, G. Walter
Cho, Seong H.
Maspero, Jorge F.
Desrosiers, Martin
Hopkins, Claire
Paggiaro, Pierluigi
Zhang, Mei
Lu, Xin
Patel, Naimish
Graham, Neil M. H.
Staudinger, Heribert
Mannent, Leda P.
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[34] Dupilumab is associated with lower rates of respiratory infections in patients with chronic rhinosinusitis with nasal polyps-Safety analysis from the SINUS-52 phase 3 trial
Bachert, C.
Gevaert, P.
Lee, S. E.
Kanesa-Thasan, N.
Green, S.
Mannent, L. P.
Amin, N.
Chen, Z.
Lu, X.
Pandit-Abid, N.
Ortiz, B.
ALLERGY, 2020, 75 : 225 - 226
[35] Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials (vol 394, pg 1638, 2019
Bachert, C.
Han, J. K.
Desrosiers, M.
LANCET, 2019, 394 (10209) : 1618 - 1618
[36] Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
Maspero, Jorge F.
Khan, Asif H.
Philpott, Carl
Hellings, Peter W.
Hopkins, Claire
Wagenmann, Martin
Siddiqui, Shahid
Msihid, Jerome
Nash, Scott
Chuang, Chien-Chia
Kamat, Siddhesh
Rowe, Paul J.
Deniz, Yamo
Jacob-Nara, Juby A.
JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 323 - 332
[37] Health-Related Quality of Life Impairment Among Patients With Severe Chronic Rhinosinusitis With Nasal Polyps in the SINUS-24 Trial
Maspero, Jorge
Philpott, Carl
Hellings, Peter
Hopkins, Claire
Wagenmann, Martin
Siddiqui, Shahid
Jacob-Nara, Juby
Msihid, Jerome
Chuang, Chien-Chia
Kamat, Siddhesh
Khan, Asif
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB133 - AB133
[38] Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI ≥30 kg/m2 or weight ≥90 kg: post-hoc analysis of the SINUS-24 and SINUS-52 studies
Cho, Seong
Tan, Bruce
Cohen, Noam
Tversky, Jody
Toskala, Elina
Nash, Scott
Zhang, Haixing
Siddiqui, Shahid
Khan, Asif
Jacob-Nara, Juby
Rowe, Paul
Deniz, Yamo
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB143 - AB143
[39] Dupilumab treatment effects are observed after the first dose as measured at week 2 across atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps: Data from phase 3 SOLO 1 & 2, LIBERTY ASTHMA QUEST, and SINUS-52 studies
Weidinger, S.
Canonica, G. W.
DesRosiers, M.
Simpson, E. L.
Bastian, M.
Rice, M. S.
Chen, Z.
Mannent, L. P.
Deniz, Y.
Rowe, P.
Amin, N.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 60 - 61
[40] Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Pre/Post Assessment of Oral Corticosteroid Use and Sinus Surgery in the US
Maldonado-Puebla, Martin
Cardet, Juan Carlos
Silver, Jared
Laliberte, Francois
Hilts, Annalise
Ramasubramanian, Ramya
Zhang, Kaixin
Hwee, Jeremiah
Ahmed, Waseem
Edgecomb, Amy
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB263 - AB263

← 1 2 3 4 5 →